Cridanimod (Standard)
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer[1][2].
Product Specifications
CAS Number
38609-97-1
UNSPSC
12352005
Target
IFNAR; Progesterone Receptor
Related Pathways
Immunology/Inflammation; Vitamin D Related/Nuclear Receptor
Field of Research
Inflammation/Immunology; Cancer
Smiles
O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O
Molecular Formula
C15H11NO3
Molecular Weight
253.26
References & Citations
[1]Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016|[2]Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
